Dupilumab significantly improves inflammation, disease activity in eosinophilic gastritis

Dupilumab significantly reduced gastric eosinophilic inflammation — and improved measures of endoscopic and histologic disease — at 12 weeks compared with placebo in patients with eosinophilic gastritis, according to phase 2 trial results.Findings provide additional evidence that eosinophilic gastritis (EoG), which has no FDA-approved treatments, appears driven by the same immune